Almost all cervical cancer cases are caused by human papillomavirus (HPV) infection. Early prevention and screening are effective ways to reduce the incidence of cervical cancer. Studies have found that glycans are involved in the differentiation, migration, adhesion, invasion, and other processes of cervical cancer cells. Aberrant sialylation and fucosylation are associated with the early onset of cervical cancer. Therefore, researchers are turning to a combination of genomic and proteomic approaches to explore, analyze, and characterize the mechanisms of action of cervical cancer cells and develop new tumor biomarkers.
Fig.1 The participation of dysregulated glycosylation in cervical cancer progression. (Xu, et al., 2021)
With its advanced Glycogenomics Platform, CD BioGlyco provides clients with discovery and analysis services of glycogenes in cervical cancer cells. At present, many glycosylation genes related to the occurrence, development, and prognosis of cervical cancer have been reported, such as ST6GAL1, ST3GAL3, ST3GAL4, MUC1, GALNT7, etc. ST3Gal 4 promotes the expression of P21, and inhibits the expression of Cyclin D1, CDK4, Cyclin E1, and CDK2, causing cervical cancer HeLa cells to undergo S phase arrest, thereby inhibiting the cloning and proliferation of tumor cells. In cervical cancer tissues, the mRNA expression of ST6GAL1 is significantly increased, and single nucleotide polymorphisms in its gene promoter have been confirmed to be associated with precancerous lesions of cervical cancer.
Microarray assay, lectin blot, and enzyme-linked lectin assay are common strategies for exploring abnormal glycosylation in cervical cancer, as follows:
Fig.2 Strategies for glycogene discovery. (CD BioGlyco)
CD BioGlyco has an advanced glycogenomics platform and an experienced team of scientists, committed to providing clients with high-quality glycogenomics services. If you have any needs regarding glycogenes, please feel free to contact us.